Form 4: 5AM Partners VI Boosts Camp4 Therapeutics Stake

5AM Partners VI, a significant shareholder and director, acquired over 2.9 million shares of Camp4 Therapeutics common stock at $1.53 per share.

Summary

• 5AM Partners VI, LLC, identified as a Director and 10% Owner of Camp4 Therapeutics Corp (CAMP), reported an acquisition of common stock.
• The transaction involved the purchase of 2,941,176 shares of common stock.
• The shares were acquired at a price of $1.53 per share.
• The transaction date was September 11, 2025.
• Following this transaction, the reporting person beneficially owns 2,941,176 shares indirectly through 5AM Ventures VII, L.P., 2,625,145 shares indirectly through 5AM Ventures VI, L.P., and 302,770 shares indirectly through 5AM Opportunities II, L.P.
• The filing indicates the transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 9

Explanation: The sentiment is highly positive due to a significant insider purchase by a major institutional investor and director, signaling strong confidence in the company's future.

Positives

• A significant insider purchase by a 10% owner and director signals strong confidence in Camp4 Therapeutics' future prospects.
• The acquisition of 2,941,176 shares represents a substantial investment by 5AM Partners VI, LLC.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned investment strategy.

Future Outlook

The significant insider purchase by a major shareholder and director suggests a positive outlook on the company's future performance and valuation by key stakeholders.

Management Comments

• Dr. Kush Parmar, Managing Member of 5AM Partners VI, LLC, signed the filing, indicating his involvement in the reported transaction and beneficial ownership structure.

Industry Context

Insider buying, especially by a 10% owner and director, is often viewed as a strong positive signal in the biotechnology sector, indicating confidence in the company's pipeline, strategic direction, or upcoming milestones, potentially differentiating it from competitors facing similar market conditions.

Comparison to Industry Standards

• Insider purchases of this magnitude (over $4.5 million) by a venture capital firm that is also a 10% owner and has board representation are generally considered a strong vote of confidence, often exceeding typical open-market purchases by individual executives.
• Such investments are comparable to strategic investments seen in early-stage or growth-phase biotech companies where existing institutional investors deepen their commitment, signaling belief in long-term value creation.

Related Party Transactions

• The transaction involves 5AM Partners VI, LLC, a 10% owner and director of Camp4 Therapeutics Corp, acquiring shares from the issuer, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Likely to view the significant insider purchase as a positive signal, potentially increasing investor confidence and demand for the stock.
• Company: Receives capital from the share issuance, which can be used for operations, research, or other strategic initiatives.

Key Dates

Recommendation

The substantial insider purchase by a 10% owner and director, 5AM Partners VI, LLC, at a price of $1.53 per share, indicates a strong vote of confidence in Camp4 Therapeutics' future prospects. Such a significant investment by a well-informed party suggests potential undervaluation or anticipated positive developments, making it a compelling 'strong buy' signal for seasoned investors.

Keywords

Camp4 Therapeutics, CAMP, 5AM Partners VI, Insider Buying, Stock Acquisition, Biotechnology, Venture Capital, SEC Form 4, Equity Investment